FCB unit to win $30 mil biotech acc't

Published on .

Biotech company Amgen is expected to award an estimated $30 million direct-to-consumer account to FCB Worldwide's FCB Healthcare, New York. FCB will handle creative and media for Neupogen, a drug that helps fight infection after chemotherapy. An Amgen spokesman said the company is in final talks with FCB. FCB declined to comment.

Copyright July 2000, Crain Communications Inc.

Most Popular
In this article: